Literature DB >> 8083562

Systemic absorption and anticholinergic activity of topically applied tropicamide.

M L Vuori1, T Kaila, E Iisalo, K M Saari.   

Abstract

We studied the plasma levels and systemic anticholinergic activity of tropicamide after ocular administration in eight women. Two 40 microliters drops of 0.5% tropicamide were instilled into the lower cul-de-sac of one eye of the subjects and concentrations and respective muscarinic receptor occupancy of tropicamide in plasma were monitored using radioligand binding techniques. Tropicamide was rapidly absorbed systemically with the mean peak concentration in plasma being 2.8 +/- 1.7 ng/ml (mean +/- SD) at five minutes after instillation. Tropicamide disappeared rapidly from the systemic circulation: drug concentration in plasma was 0.46 +/- 0.51 ng/ml (mean +/- SD) at 60 minutes and below 240 pg/ml at 120 minutes after instillation. Tropicamide bound to muscarinic receptors of rat brain with an apparent equilibrium binding constant (Ki-value in plasma) 220 +/- 25 nM (mean +/- SD, n = 3). Tropicamide occupied maximally 8% of muscarinic receptors in plasma after ocular application. The low affinity of tropicamide for muscarinic receptors and its negligible receptor occupancy in plasma can explain the low incidence of systemic side-effects of tropicamide eyedrops.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083562     DOI: 10.1089/jop.1994.10.431

Source DB:  PubMed          Journal:  J Ocul Pharmacol        ISSN: 8756-3320


  8 in total

1.  The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide.

Authors:  Surabi Veeraragavan; Nghiem Bui; Jennie R Perkins; Lisa A Yuva-Paylor; Richard Paylor
Journal:  Behav Neurosci       Date:  2011-10       Impact factor: 1.912

2.  Characterizing Current Attitudes and Practices for Human Subject Safety in Studies Involving Pupil Dilation.

Authors:  Jacob Szpernal; Joseph Carroll; Ryan Spellecy; Jane A Bachman Groth
Journal:  J Empir Res Hum Res Ethics       Date:  2020-11-02       Impact factor: 1.742

3.  Effects of unilateral topical administration of 0.5% tropicamide on anterior segment morphology and intraocular pressure in normal cats and cats with primary congenital glaucoma.

Authors:  Filipe Espinheira Gomes; Ellison Bentley; Ting-Li Lin; Gillian J McLellan
Journal:  Vet Ophthalmol       Date:  2011-09       Impact factor: 1.644

4.  Efficacy and safety of intraoperative use of tropicamide 0.02%/phenylephrine0.31%/lidocaine1% intracameral combination during pediatric cataract surgery.

Authors:  Paolo Nucci; Andrea Lembo; Roberto Caputo; Andrea Dellavalle; Massimiliano Serafino; Irene Schiavetti; Francesco Pichi
Journal:  Int Ophthalmol       Date:  2022-09-02       Impact factor: 2.029

5.  Pupillary Dilation in Research: More than Meets the Eye.

Authors:  Jacob Szpernal; Jane A Bachman Groth; Niamh Wynne; Vesper Williams; Ryan Spellecy; Catherine Thuruthumaly; Joseph Carroll
Journal:  Curr Eye Res       Date:  2022-05-02       Impact factor: 2.555

6.  Near fatal anticholinergic intoxication after routine fundoscopy.

Authors:  G A Brunner; S Fleck; T R Pieber; A Lueger; P Kaufmann; K H Smolle; H Brussee; G J Krejs
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

7.  The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors.

Authors:  Adrienne J Betz; Peter J McLaughlin; Melissa Burgos; Suzanne M Weber; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2007-06-27       Impact factor: 4.530

Review 8.  The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design.

Authors:  Yong Ling; Zhi-You Hao; Dong Liang; Chun-Lei Zhang; Yan-Fei Liu; Yan Wang
Journal:  Drug Des Devel Ther       Date:  2021-10-13       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.